IP & TECHNOLOGY

In August 2021, TheraPten obtained a US patent covering the PR61 cDNA & protein with broad Composition of Matter claims. Projected expiry is in 2040, excluding SPC and data exclusivity protection (additional 5+1 yrs).

The US patent was carved out from a pending worldwide (PCT) patent claiming PR61 and several other cell-permeable PTENs. The PCT application was filed in Q1/2019 and entered national phase in the major markets (US, EU, CN, JP) in Q3 2021.